27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!

When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Get in on the action here.

Peter Maag Insider Information

Insider of CareDx


Peter Maag is the executive chairman and CEO of CareDx, a biotechnology company. 

Maag first joined CareDx in 2012 as its president and CEO, a position he held until 2020. In January 2020, he was named chairman of the board, taking on the role of executive chairman in November 2020. 

Prior to CareDx, Maag spent a decade with Novartis, beginning as the company’s head of strategy in 2001. During his tenure, Maag helped spearhead new ventures in the company’s molecular diagnostics, along with heading up the expansion of Novartis’ blood screening business worldwide. His most recent position with the company was as president of diagnostics from 2009 to 2012, but he also worked as Novartis’ country president in Germany and Korea. 

Maag began his career in the pharmaceutical and diagnostic industry as an associate principal with McKinsey & Co from 1994 to 2001, working in Berlin and New Jersey on globalization and pharmaceutical strategies. 

Maag currently serves as a board member for PHOENIX Group (Mannaheim) and MolecularMD. He studied pharmaceutical sciences at both the University of London and the University of Heidelberg and received his Ph.D. from the University of Berlin, Germany.

What is Peter Maag's net worth?

The estimated net worth of Peter Maag is at least $6.98 million as of April 5th, 2022. Dr. Maag owns 311,689 shares of CareDx stock worth more than $6,984,950 as of July 4th. This net worth approximation does not reflect any other investments that Dr. Maag may own. Additionally, Dr. Maag receives an annual salary of $791,450.00 as Insider at CareDx. Learn More about Peter Maag's net worth.

How old is Peter Maag?

Dr. Maag is currently 55 years old. There are 6 older executives and no younger executives at CareDx. Learn More on Peter Maag's age.

What is Peter Maag's salary?

As the Insider of CareDx, Inc, Dr. Maag earned a total compensation package of $6,400,015.00 in 2020. Dr. Maag earned a salary of $488,700.00, stock awards of $3,327,600.00, options awards of $1,721,935.00, non-equity compensation of $860,220.00, and other compensation of $1,560.00.There are 2 executives that earn more than Dr. Maag. The highest earning executive at CareDx is Dr. Reginald Seeto, Pres, CEO & Director, who commands a salary of $1,510,000.00 per year. Learn More on Peter Maag's salary.

How do I contact Peter Maag?

The corporate mailing address for Dr. Maag and other CareDx executives is 1 TOWER PLACE 9TH FLOOR, SOUTH SAN FRANCISCO CA, 94080. CareDx can also be reached via phone at (415) 287-2300 and via email at [email protected] Learn More on Peter Maag's contact information.

Has Peter Maag been buying or selling shares of CareDx?

Peter Maag has not been actively trading shares of CareDx during the past quarter. As an example of a recent trade by , 0 shares of the stock in a transaction dated Monday, July 4th. Learn More on Peter Maag's trading history.

Who are CareDx's active insiders?

CareDx's insider roster includes Paul Adler (CEO), George Bickerstaff, III (Director), Ankur Dhingra (CFO), Michael Goldberg (Director), William Hagstrom (Director), Sasha King (CMO), Peter Maag (Insider), Reginald Seeto (Insider), Ralph Snyderman (Director), and Thomas Thomas (Director). Learn More on CareDx's active insiders.

Are insiders buying or selling shares of CareDx?

In the last twelve months, CareDx insiders bought shares 1 times. They purchased a total of 5,000 shares worth more than $211,700.00. In the last twelve months, insiders at the sold shares 27 times. They sold a total of 156,443 shares worth more than $8,087,835.54. The most recent insider tranaction occured on May, 11th when Director Grace Colon sold 5,179 shares worth more than $119,168.79. Insiders at CareDx own 4.6 % of the company. Learn More about insider trades at CareDx.

Information on this page was last updated on 5/11/2022.

Peter Maag Insider Trading History at CareDx

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/5/2022Sell10,000$38.64$386,400.00311,689View SEC Filing Icon  
3/7/2022Sell10,000$32.81$328,100.00View SEC Filing Icon  
2/7/2022Sell10,000$42.07$420,700.00View SEC Filing Icon  
1/5/2022Sell10,000$44.45$444,500.00View SEC Filing Icon  
12/6/2021Sell10,000$41.62$416,200.00View SEC Filing Icon  
11/5/2021Sell10,000$49.40$494,000.00View SEC Filing Icon  
10/5/2021Sell10,000$64.67$646,700.00View SEC Filing Icon  
9/7/2021Sell10,000$73.68$736,800.00View SEC Filing Icon  
8/5/2021Sell10,000$83.13$831,300.00356,202View SEC Filing Icon  
7/6/2021Sell10,000$90.70$907,000.00374,256View SEC Filing Icon  
6/24/2021Sell9,605$95.30$915,356.50372,258View SEC Filing Icon  
6/9/2021Sell2,522$90.00$226,980.00374,466View SEC Filing Icon  
6/7/2021Sell26,500$86.25$2,285,625.00393,977View SEC Filing Icon  
5/25/2021Sell10,000$80.59$805,900.00419,444View SEC Filing Icon  
5/10/2021Sell26,293$68.94$1,812,639.42412,757View SEC Filing Icon  
5/5/2021Sell10,000$73.32$733,200.00419,444View SEC Filing Icon  
5/3/2021Sell20,000$76.64$1,532,800.00420,343View SEC Filing Icon  
4/5/2021Sell10,000$72.40$724,000.00421,468View SEC Filing Icon  
3/5/2021Sell10,000$61.29$612,900.00View SEC Filing Icon  
2/5/2021Sell10,000$89.82$898,200.00View SEC Filing Icon  
1/5/2021Sell10,000$71.92$719,200.00431,974View SEC Filing Icon  
12/7/2020Sell10,000$66.37$663,700.00431,974View SEC Filing Icon  
11/5/2020Sell10,000$53.48$534,800.00427,689View SEC Filing Icon  
10/5/2020Sell10,000$42.11$421,100.00431,974View SEC Filing Icon  
9/30/2020Sell16,992$37.59$638,729.28438,966View SEC Filing Icon  
9/8/2020Sell10,000$31.68$316,800.00431,974View SEC Filing Icon  
8/5/2020Sell13,008$36.77$478,304.16425,134View SEC Filing Icon  
7/6/2020Sell10,000$34.21$342,100.00421,974View SEC Filing Icon  
6/30/2020Sell18,182$35.07$637,642.74View SEC Filing Icon  
6/9/2020Sell1,818$35.00$63,630.00389,499View SEC Filing Icon  
6/5/2020Sell50,000$32.58$1,629,000.00391,817View SEC Filing Icon  
5/19/2020Sell30,000$32.24$967,200.00459,909View SEC Filing Icon  
3/16/2020Sell10,000$17.39$173,900.00489,909View SEC Filing Icon  
2/18/2020Sell10,000$26.62$266,200.00451,909View SEC Filing Icon  
1/15/2020Sell10,000$23.13$231,300.00429,814View SEC Filing Icon  
8/6/2019Sell50,000$28.84$1,442,000.00379,049View SEC Filing Icon  
5/13/2019Sell80,000$31.11$2,488,800.00408,406View SEC Filing Icon  
3/11/2019Sell50,000$34.23$1,711,500.00458,406View SEC Filing Icon  
11/29/2018Sell100,000$28.53$2,853,000.00408,372View SEC Filing Icon  
11/13/2018Sell50,000$26.48$1,324,000.00389,747View SEC Filing Icon  
9/4/2018Sell15,000$23.10$346,500.00439,747View SEC Filing Icon  
3/27/2018Sell15,000$7.87$118,050.00272,037View SEC Filing Icon  
8/15/2017Buy600$1.82$1,092.00107,350View SEC Filing Icon  
6/1/2015Buy2,000$4.84$9,680.00View SEC Filing Icon  
See Full Table

Peter Maag Buying and Selling Activity at CareDx

This chart shows Peter Maag's buying and selling at CareDx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

CareDx Company Overview

CareDx logo
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $22.41
Low: $21.40
High: $22.52

50 Day Range

MA: $25.05
Low: $20.49
High: $34.07

2 Week Range

Now: $22.41
Low: $19.34
High: $92.55

Volume

618,400 shs

Average Volume

817,234 shs

Market Capitalization

$1.19 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.92
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!

When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
Get in on the action here.